Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,435 across all filing types
Latest filing 2026-05-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于独立董事任期届满辞职的公告
Board/Management Information Classification · 95% confidence The document is an official company announcement stating that an independent director’s term has expired and he is resigning, discussing board member changes and upcoming election of a new independent director. This fits the definition of a Board/Management Information filing (announcement of changes in the company’s board of directors).
2026-05-20 Chinese
关于获得创新药安瑞克芬注射液术后疼痛适应症上市许可申请《受理通知书》的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by Haise Ke Pharmaceutical Group concerning receipt of an acceptance notice from the National Medical Products Administration for a new drug indication marketing approval application. It does not contain any financial statements, management discussion of financial results, capital market transactions, voting results, or meeting materials. It is a routine regulatory disclosure (disclosure of an administrative acceptance notice) and does not fit other specific categories (e.g., IR, 10-K, ER, M&A). Therefore, it should be classified under the general Regulatory Filings category (RNS).
2026-05-11 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2025 annual dividend distribution plan approved at the 2025 annual shareholders meeting. It details the dividend amount per share, the record date, the ex-dividend date, the dividend payment method, and related shareholder information. The document does not contain financial statements or comprehensive financial performance data but focuses solely on the dividend distribution details. The document length is 1845 characters, which is relatively short and typical for a dividend announcement. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2026-05-07 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 Annual General Meeting (AGM) of the company 海思科医药集团股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the 2025 annual report, financial report, board work report, auditor appointment, remuneration plans, profit distribution, and other corporate matters. The document is not the annual report itself but the official announcement of the voting results and decisions made at the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is about 4780 characters, which is consistent with a detailed voting results announcement rather than the full annual report or other filings.
2026-05-06 Chinese
北京市中伦（深圳）律师事务所关于海思科医药集团股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2025 Annual General Meeting (AGM) of Haike Medical Group Co., Ltd. It details the convening and holding procedures of the AGM, the qualifications of the convener and attendees, the voting procedures, and the voting results for various proposals at the AGM. The document does not contain the actual annual report or financial statements but focuses on the legality and validity of the AGM process and voting outcomes. This type of document is a legal opinion related to the AGM, not the AGM materials themselves, nor the annual report or financial results. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official results from shareholder votes at the AGM.
2026-05-06 Chinese
关于使用闲置自有资金进行委托理财的公告
Regulatory Filings Classification · 45% confidence The document is an announcement by the board of a Chinese listed company regarding the use of idle self-owned funds (up to RMB 1 billion) to purchase short-term, low-risk bank wealth management products. It is a corporate treasury management notice, not a report of financial results, share issuance, board changes, dividends, proxies, or M&A. It does not involve raising new capital or changes in capital structure. There is no detailed financial report or Excel data; rather, it is a formal regulatory announcement of a financing/investment action using own funds. This falls outside the narrow specialized categories and is best classified under the fallback category “Regulatory Filings” (RNS).
2026-04-12 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.